Fox Run Management, L.L.C. Mersana Therapeutics, Inc. Transaction History

Fox Run Management, L.L.C.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$2.16 - $5.94 $26,483 - $72,830	12,261 New	12,261 $54,000
Q3 2023 Nov 07, 2023	BUY	$1.06 - $3.91 $23,139 - $85,355	21,830 New	21,830 $27,000
Q4 2022 Feb 07, 2023	BUY	$5.65 - $7.86 $71,003 - $98,776	12,567 Added 103.99%	24,652 $144,000
Q3 2022 Nov 07, 2022	BUY	$4.63 - $8.0 $55,953 - $96,680	12,085 New	12,085 $82,000
Q4 2021 Feb 09, 2022	SELL	$5.48 - $9.86 $64,548 - $116,140	-11,779 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$8.56 - $14.47 $100,828 - $170,442	11,779 New	11,779 $111,000

126

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $55.4M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.